An Overview of Arrhythmogenic Right Ventricular Cardiomyopathy

A cause of sudden death in young athletes

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic condition in which normal cardiac muscle becomes replaced with fibrous, fatty tissue, mainly in the right ventricle. It is one of the cardiac conditions associated with sudden death in young athletes.

ARVC is uncommon, but not rare. It would be found in 1 out of every 2,000 to 5,000 adults if they were are evaluated for it.

Echocardiogram and ECG illustration
Stegerphoto / Getty Images

ARVC was formally known as arrhthmogenic right ventricular dysplasia.

ARVC Symptoms

While ARVC is a cardiomyopathy—that is, a heart muscle disease—it only rarely causes muscle problems that are extensive enough to produce heart failure.

Rather, its clinical significance is that it can cause abnormal heartbeats (cardiac arrhythmias). In particular, ARVC can cause premature ventricular complexesventricular tachycardia, and sometimes ventricular fibrillation.

The symptoms caused by ARVC are usually related to the arrhythmias it may produce. People with ARVC will commonly describe episodes of one or more of the following:

Sudden death may also occur. Unfortunately, it may be the very first sign that there is any heart problem.

Approximately 5% to 10% of people with ARVC will have no symptoms whatsoever, or the first symptom will be death. Some of these people are diagnosed when they are screened for the disorder because a family member has been diagnosed with it.

While ARVC can cause sudden death at any time, this event appears to be more likely to occur during episodes of physical exertion than at rest. This is why ARVC is one of the conditions that produces sudden death in apparently healthy, young athletes.

However, because this can also occur during routine activity or at rest, refraining from exercise is generally not enough to alleviate the risk in people with ARVC.


Doctors can diagnose ARVC by examining the results of two tests:

  • Electrocardiogram (ECG or EKG), which often shows a particular configuration of the QRS complex (a waveform showing electrical activity in the heart before the ventricles contract)
  • Echocardiogram (echo), which often shows characteristic abnormalities in the cardiac muscle of the right ventricle (and sometimes of the left ventricle)

If the diagnosis or risk of sudden death remains in doubt, sometimes cardiac magnetic resonance imaging (MRI) can help pin things down.

Genetic testing can also be helpful in making the diagnosis and is recommended for all people who have this condition so their relatives can be screened.

While electrophysiologic testing can occasionally be helpful in distinguishing ventricular tachycardia due to ARVC from ventricular tachycardia caused by other cardiac conditions, such testing is not routinely helpful and is usually not required.

Once the diagnosis is made, genetic screening is also recommended for first-degree relatives. About 1 in 3 first-degree relatives of a person with ARVC will also eventually develop this condition.


The main goal in treating ARVC is to prevent sudden cardiac death from ventricular tachycardia or fibrillation. This may be done with:

  • Activity restrictions
  • Medication
  • An implantable defibrillator

Activity Restrictions

The arrhythmias associated with ARVC appear to be brought out by sympathetic stimulation—the part of the autonomic nervous system that increases adrenaline levels and is responsible for the fight-or-flight response. This is why exercise is a problem with ARVC.

Because sudden death is often associated with exercise in this condition, athletes who have ARVC should refrain from all competitive sports, with the possible exception of low-intensity activities such as golf or bowling.

Furthermore, they should refrain from any activity that produces significant palpitations or syncope.

Asymptomatic people are also warned that intense exercise increases the risk of developing ARVC symptoms including sudden death.


Most cardiologists treating this condition recommend the use of beta blockers to blunt the effect of adrenaline in the heart.

However, for people with ARVC who have no high-risk features on evaluation and no symptoms, treatment may or may not include beta blockers.

The American Heart Association and American College of Cardiology suggest a beta blocker may be useful,while the Heart Rhythm Society doesn't believe there is enough evidence to support long-term beta-blocker treatment for unaffected carriers of the gene responsible for ARVC.

Some people may also be prescribed an antiarrhythmic drug.


Implantable defibrillators are frequently recommended for people with ARVC, especially when any of the following apply:

  • A person has experienced an episode of cardiac arrest
  • A person has experienced an episode of sustained ventricular tachycardia
  • A person has experienced an episode of unexplained syncope
  • Imaging shows extensive involvement of the cardiac muscle

In people with ARVC who have had sustained ventricular arrhythmias, the long-term prognosis appears to be improved if they avoid exercise, take beta blockers, receive an implantable defibrillator, and (in some cases) take an antiarrhythmic drug. Prognosis also depends on which parts of the heart are involved and other individual factors.

A Word From Verywell

Arrhythmogenic right ventricular cardiomyopathy is a genetic condition that can produce potentially lethal cardiac arrhythmias, including those that cause sudden death in young athletes.

In some cases, ARVC goes undetected until sudden death occurs, so it's important to get tested in you have this condition in your family. With aggressive treatment, people with ARVC typically do quite well.

6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Romero J, Mejia-Lopez E, Manrique C, Lucariello R. Arrhythmogenic right ventricular cardiomyopathy (ARVC/D): A systematic literature review. Clin Med Insights Cardiol. 2013 May;7(1):97-114. doi:10.4137CMC.S10940

  2. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015 Dec;36(46):3227-3237. doi:10.1093/eurheartj/ehv162 

  3. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015 Mar;8(3):437-446. doi:10.1161/CIRCGENETICS.114.001003

  4. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 May;16(11):e301-e372. doi:10.1016/j.hrthm.2019.05.007

  5. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct;72(14):91-220. doi:10.1016/j.jacc.2017.10.054

  6. Aquaro GD, De Luca A, Cappelletto C, et al. Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy. Journal of the American College of Cardiology. 2020 Jun;75(22):2753-2765. doi:10.1016/j.jacc.2020.04.023

By Richard N. Fogoros, MD
Richard N. Fogoros, MD, is a retired professor of medicine and board-certified in internal medicine, clinical cardiology, and clinical electrophysiology.